Vimarsana
Biggest News Aggregation in the World

Page 5 - Briggs Morrison News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Briggs Morrison. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Briggs Morrison Today - Breaking & Trending Today

Crossbow Therapeutics' novel antibody therapies financed with $80 million Series A - Vimarsana News

Crossbow Therapeutics' novel antibody therapies financed with $80 million Series A

Crossbow Therapeutics, a biotech company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced a $80 million Series A funding round.

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class ... - Vimarsana News

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class ...

Proprietary T-Bolt™ technology dramaticallybroadens the benefits of immunotherapy by targeting the entire universe of cancer antigens

Crossbow Therapeutics Raises $80M in Series A Financing - Vimarsana News

Crossbow Therapeutics Raises $80M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Guggenheim Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) - Vimarsana News

Guggenheim Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)

Investment analysts at Guggenheim initiated coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) in a report issued on Monday, FlyOnTheWall reports. The brokerage set a “buy” rating on the stock. Other equities research analysts have also issued reports about the company. Citigroup decreased their price target on Syndax Pharmaceuticals from $32.00 to […]

Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $33.86 - Vimarsana News

Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $33.86

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) has been given an average rating of “Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock […]

Source: wkrb13.com